^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Gastric Cancer
    Drug:Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

    Excerpt:
    ...Patients with PIK3CA mutation and/or PIK3CA amplification 7....
    Trial ID:
    NCT02451956
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Transl Med
    Title:

    The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

    Excerpt:
    Our data indicated that AZD5363 monotherapy treatment led to a moderate response in the PI3KCA mutant PDGCX model. Whilst monotherapy AZD5363 or Taxotere were ineffective in the PTEN negative PDGCX model, significant anti-tumor activity was observed when AZD5363 was combined with Taxotere.
    DOI:
    10.1186/1479-5876-11-241